Vitamin D treatment improves levels of sexual hormones, metabolic parameters and erectile function in middle-aged vitamin D deficient men.
Aging Male. 2017 Mar;20(1):9-16. doi: 10.1080/13685538.2016.1271783. Epub 2017 Jan 11.
100 males with vitamin D levels < 30ng, average age 53
Loading dose of 600,000 IU of vitamin D2
Followed up with maintenance dosing of 600,000 IU every 1, 2, or 3 months
Suspect that they meant 60,000 IU of Vitamin D, not 600,000 IU
Aiming for <80 nanogram level of vitamin D
|TT (total testosterone)||12||16||nmol|
|Erectile function scores||14||20||-|
See also VitaminDWiki
- Fertility and sperm category listing has
69 items along with related searches
- Male fertility 4 X higher if high Vitamin D – Nov 2015
- Total Testosterone, Erectile function scores, etc improved with loading dose of Vitamin D2 - Jan 2017
- Erectile Dysfunction associated with low vitamin D in several studies
- Search VitaminDWiki for "erectile dysfunction" 34 items as of March 2017
- Prostate Cancer and Vitamin D studies PSA
- Dieters lost 5 more pounds if achieved more than 32 ng of vitamin D – RCT March 2014
- Overweight and obese lost 12 lbs with vitamin D in 6 months– RCT May 2015
- Overview Loading of vitamin D
Items in both of the categories Intervention AND Fertility/Sperm
Suspect that 50,000 Vitamin D3 bottle costing less than $20 would provide similar results: 1 capsule per day for 8 days then 1 capsule per week for a year
Canguven O1, Talib RA1, El Ansari W2, Yassin DJ3, Al Naimi A1.
1 Department of Urology
2 Department of Surgery , Hamad General Hospital, Hamad Medical Corporation , Doha , Qatar
3 Institute of Urology and Andrology , Hamburg , Germany.
Vitamin D levels
Erectile function levels
The associations between serum vitamin D (VD), serum testosterone (TT) and metabolic syndrome are complex and with limited published research, particularly on the effects of VD treatment on sexual hormones, erectile function and the metabolic syndrome.
This study assessed whether a monthly high dose VD treatment for 12 months in VD deficient middle-aged men was associated with: changes in levels of sexual hormones, improvement of diabetes control and metabolic syndrome components, better erectile function [International Index of Erectile Function (IIEF)-5 questionnaire]; and changes in a prostate marker.
MATERIALS AND METHODS:
Descriptive research of a prospective study, conducted between October 2014 and September 2015, 102 male patients ≥35 [(±SD: 53.2 ± 10.5), (range 35-64)] years with deficient serum VD level (<30 ng/mL) were included in the study. Participants were followed up for one year, with monitoring at 3-, 6-, 9- and 12-months. At the initial baseline visit, a complete medical examination was conducted, and blood was drawn for laboratory tests for above biochemical and hormonal variables under examination. Participants received an initial VD (Ergocalciferol; oral solution 600 000 IU/1.5 ml), and followed a VD treatment regime thereafter. At the four follow up visits (3, 6, 9 and 12 months), blood was collected, and patients' erectile function was evaluated by IIEF-5 questionnaire.
MAIN OUTCOME MEASURES:
During the follow up visits, all the biochemical and hormonal (TT, estradiol and luteinizing hormones, HbA1c, serum lipids profile) were assessed, and patients' erectile function was evaluated by IIEF-5 questionnaire.
Patients' mean age was 53.2 ± 10.4 years. Serum VD exhibited significant increments (p <0.001) from baseline (15.16 ± 4.64 ng/mL), to 3 (31.90 ± 15.99 ng/mL), 6 (37.23 ± 12.42 ng/mL), 9 (44.88 ± 14.49 ng/mL) and 12 months (48.54 ± 11.62 ng/mL), and there was significant stepladder increases in both serum TT level (12.46 ± 3.30 to 15.99 ± 1.84 nmol/L) and erectile function scores (13.88 ± 3.96 to 20.25 ± 3.24) (p <0.001 for both). We also observed significant stepladder decreases in estradiol (87.90 ± 27.16 to 69.85 ± 14.80 pmol/L, p = 0.001), PTH (from 58.52 ± 28.99 to 38.33 ± 19.44 pg/mL, p <0.001) and HbA1c levels (7.41 ± 2.85 to 6.66 ± 1.67%, p = 0.001). Mean BMI significantly decreased from 33.91 ± 6.67 to 33.14 ± 6.35 kg/m2 (p = 0.001); and PSA values significantly increased from 0.59 ± 0.30 to 0.82 ± 0.39 ng/mL (p <0.001) at the end of the 12 months' follow-up. There were no changes in LH levels.
This study demonstrated that VD treatment improves testosterone levels, metabolic syndrome and erectile function in middle-aged men. More randomized placebo-controlled interventional trials of VD treatment in patients with the metabolic syndrome and low TT could assist in uncovering the putative roles of VD.
PMID: 28074679 DOI: 10.1080/13685538.2016.1271783
362 visitors, last modified 23 Sep, 2017, URL:This page is in the following categories (# of items in each category)Obesity 266 Fertility and sperm 69 Intervention 438 Top news 610